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INTRODUCTION
In 2012, more than 1800 patients were newly diagnosed with 
acute myeloid leukemia (AML) in Korea, and about 33.7% of 
those patients were 65 years of age or older.1 Due to comorbidi-
ties, poor performance status, and elevated risks associated 
with older age in patients with AML, such patients are often in-
eligible for intensive chemotherapy or participation in clinical 
trials. Therefore, their treatment options are limited, and treat-
ments that are less intensive than conventional chemotherapy 
have been proposed. Decitabine, or 5-aza-2’-deoxycytidine, is a 
cytosine analogue that was first synthesized in 1968 by Sorm 
and Veselý.2 The potential activity of decitabine against leuke-
mia was first reported in 1968.2 Decitabine was originally devel-
oped to be used at high doses as an antimetabolite, although 
low-dose therapy is now more commonly used than high-dose 
therapy.3 When used at low doses, decitabine is incorporated 
into DNA and degrades DNA methyltransferases (DNMTs) by 
covalent trapping,4 resulting in hypomethylation of DNA and 
reactivation of silenced gene expression, which can reactivate tu-
mor-suppressor genes and promote apoptosis of leukemic 
blasts in the absence of DNMTs.5 However, the exact anti-leu-
kemic mechanism of decitabine is still unclear, as correlations 
between hypomethylation, gene re-expression, and clinical re-
sponse have not yet been determined.6,7 Other potential mech-
anisms, such as the generation of intracellular reactive oxygen 
species, have been suggested.8,9
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So far, several studies have demonstrated that decitabine is ef-
fective against AML and shows tolerable toxicity profiles in pa-
tients of older age.10,11 However, the United States Food and Drug 
Administration did not approve decitabine for the treatment of 
newly diagnosed AML based on the results of a clinical trial re-
ported by Kantarjian, et al.12 in 2012. In that study, decitabine 
treatment for older adults with newly diagnosed AML did not 
provide a statistically significant survival improvement, com-
pared with supportive care or low-dose cytarabine therapy at 
the pre-planned, prospectively defined time point. However, in 
the same study, decitabine treatment did show a survival benefit 
over standard therapies in an unplanned survival analysis (me-
dian survival 7.7 months vs. 5.0 months; p=0.037). Based on that 
result, the European Medicines Agency Committee for Medici-
nal Products for Human Use approved decitabine as a first-line 
treatment for older adults with AML in 2012. Although the exact 
role and proper indications of decitabine for older adults with 
AML are still controversial, the Korean Food and Drug Admin-
istration (KFDA) recently approved decitabine as a first-line 
treatment for the same indications as those of European Union 
in December 2013. Since gaining KFDA approval, the number 
of older Korean patients with AML who are not candidates for 
standard induction chemotherapy and are instead treated with 
decitabine as the first-line therapy has been increasing. As na-
tional data relating to the clinical outcomes of decitabine treat-
ment for older adults with newly diagnosed AML have not been 
reported, we conducted a retrospective study to evaluate safety, 
clinical efficacy, and factors affecting treatment responses us-
ing data from older adults with AML who were treated with 
decitabine as the first-line therapy at Severance Hospital in 
Seoul, Korea.
MATERIALS AND METHODS
Patients
Clinical data from patients diagnosed with de novo or second-
ary AML, excluding acute promyelocytic leukemia and isolated 
myeloid sarcoma, between December 1, 2013 and May 31, 2015 
at Severance Hospital in Korea were retrospectively reviewed. 
Twenty-four patients treated with decitabine as the first-line 
therapy for remission induction were included. AML was diag-
nosed according to the 2008 World Health Organization crite-
ria.13 Patients with a prior history of other malignancy were in-
cluded, while patients who were treated with hypomethylating 
agents, such as decitabine or azacitidine, before being diag-
nosed with AML were excluded. The end point of the study was 
July 23, 2015 or the time of death or loss from follow-up. Treat-
ment response, overall survival (OS), progression-free survival 
(PFS), treatment toxicity, and factors affecting the treatment re-
sponse were analyzed. The study was approved by the Institu-
tional Review Board of Severance Hospital at Yonsei University 
College of Medicine in Seoul, South Korea.
Treatment, response, and toxicity
All patients were treated with at least one course of low-dose 
decitabine at an initial dose of 20 mg/m2 intravenously daily for 
5 days over 28-day cycles. Responses after decitabine treatment 
were assessed according to the 2003 International Working 
Group criteria.14 Specifically, a complete response (CR) was de-
fined as bone marrow (BM) blasts less than 5%, platelet count 
greater than 100000/μL, white blood cell (WBC) count greater 
than 1000/μL, and no extramedullary leukemia. CR with incom-
plete blood-count recovery (CRi) was defined as CR status 
without a platelet count greater than 100000/μL or a WBC count 
greater than 1000/μL. Partial remission (PR) was defined as at 
least a 50% decrease in the percentage of BM blasts to 5–25%. 
No response (NR) was defined as a failure to achieve CR or PR 
or as death before day 28 of the first cycle of decitabine therapy. 
Loss of response (LOR) was defined as an initial CR or PR with 
a subsequent increase of BM blasts of more than 25% relative to 
the previous BM blast percentage. To analyze factors affecting 
treatment response, we divided the patients into two groups: 
responders and non-responders. Responders were defined as 
patients who achieved CR or CRi after decitabine treatment. 
Non-responders were defined as patients who did not achieve 
CR or CRi after decitabine treatment. The treatment response 
was not defined for patients who did not receive a response 
evaluation after a minimum of four cycles of treatment, unless 
there was clear evidence of a lack of response before the fourth 
cycle. Patients showing CR, CRi, or PR continued receiving cy-
clic decitabine treatment, and those showing NR or LOR could 
be considered as having treatment failure and received second-
line treatment according to the physician’s decision. Treatment 
toxicity was assessed according to the Common Terminology 
Criteria for Adverse Events version 4.0.
Assessment of clinical outcomes
OS was measured from the starting date of the first decitabine 
treatment to date of death (any cause). PFS was measured from 
the starting date of the first decitabine treatment to the first 
documented date of NR, LOR, or death (any cause). The dura-
tion of the treatment response was measured from the first 
documented date of a treatment response of at least PR to the 
first documented date of LOR or death.
Statistical analysis 
The Kaplan-Meier method was used to describe OS and PFS. 
Frequencies were compared between groups using chi-square 
or Fisher’s exact tests. The Mantel-Haenszel chi-square test was 
used to compare linear trends in ordinal variables between 
groups. Mann-Whitney U-tests were applied for continuous 
variables. Two-tailed p values less than 0.05 were considered 
significant. All statistical analyses were performed using SPSS 
version 20.0 (IBM Corp., Armonk, NY, USA).
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RESULTS
Patient characteristics
A total of 24 patients (12 males and 12 females) diagnosed with 
AML received decitabine as a first-line treatment between De-
cember 1, 2013 and May 31, 2015 at Severance Hospital, Seoul, 
Korea. The baseline characteristics of the patients are shown on 
Table 1. Eleven patients (45.8%) were between 70 and 74 years 
of age, four (16.7%) were less than 70 years of age, and nine 
(37.5%) were 75 years of age or older. Twenty-two patients 
(91.7%) had de novo AML, and two had secondary AML; one 
patient had therapy-related AML with a prior history of prostate 
cancer and thyroid cancer, and the other had AML progressed 
from myelodysplastic syndromes. Until July 2015, a total of 113 
cycles of decitabine treatment were given to the 24 patients, 
and the median number of cycles was four (mean, 4.7; range, 
1–14). Twenty-one (87.5%) and 12 (50%) patients completed 
the second and the fourth cycles, respectively. A total of 13 pa-
tients were dropped from decitabine treatment because of 
death (n=2), NR or LOR (n=6), patient refusal (n=4), or transfer 
to another hospital (n=1).
Treatment responses
After the fourth cycle of decitabine treatment, 17 patients were 
evaluated by BM study to determine treatment responses (Fig. 
1). Until completion of the fourth cycle of treatment, five pa-
tients discontinued decitabine treatment because of a lack of 
response. The treatment response could not be evaluated in 
seven patients: three refused the follow-up BM study, one trans-
ferred to another hospital shortly after treatment, and three had 
not yet finished the fourth cycle of treatment and showed no 
evidence of a lack of response. Overall, 12 of 17 patients (70.6%) 
had shown a response to decitabine. The best response was CR 
or CRi in six patients (35.3%) and PR in the other six patients 
(35.3%). Eight patients (CR or CRi, 3; PR, 5) achieved their best 
response after two cycles of treatment, and four patients (CR or 
CRi, 3; PR, 1) achieved their best response after four cycles of 
treatment (median 3.0 cycles). All six patients who initially 
achieved CR or CRi maintained their treatment response until 
the end of the study period, for a median 9.0 cycles of treatment 
(range, 6–13 cycles). One patient died from pneumonia, how-
ever, despite achieving CRi status after the eighth cycle. Among 
the six patients that achieved PR as their best response, four 
maintained their treatment response until the end of the study, 
for a median 22.5 days (range, 4–189 days), although two finally 
lost their response after receiving two more and five more fur-
ther cycles of treatment, respectively. One of the four patients 
who maintained PR status until the end of the study ultimately 
died from sepsis after the fifth cycle of treatment. Five patients 
who experienced failure of decitabine treatment received a sec-
Table 1. Baseline Characteristics of All Patients, the Responders and the Non-Responders
Characteristics Total (n=24) Responders (n=6) Non-responders (n=11) p value
Age (yrs)* 73.5 (66–82) 70.5 (68–74) 73.0 (70–76) 0.103
Gender, M/F† 12/12 3/3 7/4 0.622
Performance status
0–1/2† 20/4 5/1 7/4 NS
Cytogenetic risk group† NS
Better/intermediate/poor 3/16/3 1/4/1 2/6/1
Unknown 2 0 2
Type of AML
de novo/secondary† 22/2 5/1 10/1 NS
CCI, 0/1–2/3–4/≥5† 12/10/1/1 4/1/0/1 7/3/1/0 0.849
BM iron stain 2.0 (0–6) 2 (0–2) 3 (2–6) 0.033‡
Laboratory values*
WBC (×103/μL) 6.74 (0.68–366.15) 5.68 (1.46–14.73) 14.45 (1.05–157.77) 0.272
Hemoglobin (g/dL) 7.65 (3.9–13.4) 8.05 (6.6–13.4) 7.2 (4.2–10.5) 0.328
Platelets (×103/μL) 42.5 (5–170) 81.0 (22–170) 36.0 (13–153) 0.224
PB blast count (/μL) 741.15 (0–227, 013) 58.95 (0–3639) 4570 (0–70996.5) 0.061
BM blasts (%) 47.1 (2.4–88.7) 35.5 (22.2–70.5) 71.4 (27.6–88.7) 0.027
LDH (IU/L) 337.5 (161–9361) 274.5 (161–438) 448.5 (251–9361) 0.049
Creatinine (mg/dL) 0.855 (0.5–1.6) 0.72 (0.6–1.1) 0.82 (0.6–1.1) 0.475
Ferritin (ng/mL) 620.8 (71.4–15000) 337.7 (71.4–362.0) 933.3 (273.7–15000) 0.036
CRP (mg/L) 20.7 (0.6–329.2) 7.3 (0.6–85.6) 70.75 (3.3–329.2) 0.162
Cycles of Tx, median (range) 4 (1–14) 8 (6–14) 2 (1–7) 0.001
M, male; F, female; AML, acute myeloid leukemia; CCI, Charlson comorbidity index; WBC, white blood cell; PB, peripheral blood; BM, bone marrow; LDH, lactate 
dehydrogenase, CRP, C-reactive protein; Tx, decitabine treatment.
*Median (range), †Number, ‡Mantel-Haenszel chi-square test for linear trends.
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ond-line therapy. The second-line regimens were FLAG-IDA 
(composed of fludarabine, cytarabine, idarubicin, and granulo-
cyte colony-stimulating factor) for three patients, standard 7+3 
regimen (composed of cytarabine and idarubicin) for one pa-
tient, and low-dose cytarabine for one patient. No patients re-
ceived any type of hematopoietic stem cell transplantation.
Factors affecting the treatment response
To assess clinical and laboratory factors affecting the treatment 
responses, the patients were divided into two groups according 
to their response to decitabine treatment. Six patients were 
considered responders, and 11 patients were considered non-
responders. The differences in clinical characteristics between 
the groups are summarized in Table 1. One non-responder was 
not tested for baseline ferritin level and was excluded from the 
corresponding analysis. Univariate analysis showed that the re-
sponders had lower baseline serum ferritin levels than the non-
responders [337.7 ng/mL (range, 71.4–362.0) vs. 933.3 ng/mL 
(range, 273.7–15000); p=0.036] (Fig. 2A). All of the responders 
and only three of the 10 non-responders had serum ferritin lev-
els lower than 500 ng/mL (p=0.011). There was also a signifi-
cant difference in BM iron-stain grade. The responders had sig-
nificantly lower BM iron-stain grades than the non-responders 
(median 2.0 vs. 3.0; p=0.033). As expected, the BM blast per-
Fig. 1. Overall treatment responses and outcomes diagram for older patients with AML. NE, not evaluable; NR, no response; CR, complete remission; CRi, 
CR with incomplete blood-count recovery; PR, partial remission; LOR, loss of response; AML, acute myeloid leukemia.
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centage at diagnosis was significantly lower in the responders 
than in the non-responders (median 35.5% vs. 71.4%; p=0.027). 
In addition, the baseline serum lactate dehydrogenase (LDH) 
level was also significantly lower in the responders than in the 
non-responders (median 274.5 IU/L vs. 448.5 IU/L; p=0.049)
(Fig. 2B). Other baseline factors, including age, gender, cytoge-
netic risk, performance status, peripheral blood blast count, 
WBC count, hemoglobin, platelets, serum creatinine, and C-re-
active protein, were not significantly different between the re-
sponders and the non-responders. Unfortunately, it was not pos-
sible to identify any statistically significant predictive factors for 
the treatment response by multivariate analysis, because of the 
limited number of patients (data not shown).
Overall and progression-free survival
The median OS and PFS of all patients were 502 days and 201 
days [95% confidence interval (CI), 50 to 351 days], respectively, 
from the starting date of the first decitabine treatment (Fig. 3). 
Estimation of the median OS and PFS among the responders 
was impossible, because five of the six patients (83.3%) were 
still alive without evidence of disease relapse at the end of the 
study period, with a median follow-up duration of 258 days 
(range, 139–351 days). On the other hand, the median OS and 
PFS among the non-responders were 286 days (95% CI, 89 to 
483 days) and 59 days (95% CI, 33 to 85 days), respectively. Al-
though the rate of OS was higher among the responders than 
among the non-responders, there was no statistically signifi-
cant difference in OS between those groups (Fig. 4A). However, 
the rate of PFS among the responders was significantly higher 
than that among the non-responders (p=0.003) (Fig. 4B).
Fig. 3. (A) Overall (OS) and (B) progression-free survival (PFS) after decitabine treatment. The median OS and PFS of all patients were 502 days and 201 
days (95% CI, 50 to 351 days), respectively, from the starting date of the first decitabine treatment. CI, confidence interval.
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Changes of BM and peripheral blood parameters 
according to treatment 
The BM blast percentage, WBC count, hemoglobin concen-
tration, and platelet count at diagnosis and their numeric 
changes according to the treatment cycles in the patients who 
kept receiving decitabine treatment are shown in Fig. 5. As the 
decitabine treatment proceeded, the median BM blast per-
centage continuously decreased from 47.5% at diagnosis to 
6.4% after the second cycle, 2.5% after the fourth cycle, 2.1% af-
ter the sixth cycle, and 1.8% after the eighth cycle. The median 
WBC count also decreased from 7600/μL at diagnosis to 2360/
μL after the fourth cycle, and it was maintained thereafter un-
til the end of the study. The median concentration of hemoglo-
bin gradually increased from 7.8 g/dL at diagnosis to more than 
10.0 g/dL after the fifth cycle. The median platelet count was 
also recovered from 48000/μL at diagnosis to more than 
100000/μL after the third cycle.
Toxicity
The most common non-hematologic treatment-related toxici-
ties were febrile neutropenia and fatigue (Table 2). During the 
median four cycles of decitabine treatment, seven patients 
(29.2%) experienced febrile neutropenia of grade 3 or more, 
and three patients (12.5%) experienced fatigue of grade 2 or 3. 
One patient (4.2%) experienced grade 3 congestive heart fail-
ure, and one patient experienced grade 4 pulmonary thrombo-
embolism. Three patients (12.5%) refused treatment after expe-
riencing serious febrile neutropenia or fatigue, and two patients 
(8.3%) died from sepsis resulting from febrile neutropenia.
DISCUSSION
In this study, which is the first report on a Korean population, 
we showed the efficacy of decitabine against AML in older 
adults with a tolerable toxicity profile. The median OS was 286 
Fig. 5. Changes in (A) bone marrow (BM) blast, (B) white blood cell count, (C) hemoglobin, and (D) platelet count during the decitabine treatment. 
Decitabine treatment consistently reduced the fraction of BM blast, and the hemogram was also continuously improved.
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days, which might not be inferior to the results of other treat-
ment modalities reported in previous studies showing a medi-
an OS ranging from 7.5 to 10 months after intensive chemo-
therapy15-17 and of 5.0 months after supportive care or low-dose 
cytarabine.12 During the decitabine therapy, the hemograms of 
the patients gradually improved. CR rates among elderly pa-
tients after intensive chemotherapy have been reported as less 
than 50%,15-17 and the CR and CRi rates of 35.3% in this study 
seem to be remarkable. Our data did not show a significant sur-
vival difference between patients according to the treatment re-
sponse, which might be attributed to the small number of pa-
tients and the short period of the study. On the other hand, our 
data might suggest that even patients lacking a CR could have a 
substantial survival benefit with subsequent anti-leukemic 
therapy.
Finding the optimal treatment strategy for older adults with 
AML remains challenging for hematologists. Intensive chemo-
therapy based on cytarabine combined with an anthracycline, 
the so-called 7+3 regimen, has been a standard treatment for 
many years among younger patients with AML, with a CR rate 
of 70–80% and a cure rate of 40–50%.18 However, the remission 
rate after treatment with the 7+3 regimen among older individ-
uals is around 50%, and approximately 85% of elderly patients 
achieving CR experience relapse within 2 to 3 years.18 Hence, 
less intensive chemotherapy might be an alternative approach 
to treat older patients with AML. In the phase I study of 
decitabine against AML,3 a 15 mg/m2 10-day dosing regimen 
was suggested as optimal and well tolerable. In the phase II 
study of decitabine against AML, with a schedule of 20 mg/m2 
for 5 consecutive days in patients more than 60 years of age as 
the first-line treatment, the overall response rate was 25% and 
the median OS was 7.7 months.10 The primary toxicity was infec-
tion and cytopenia, and up to 47.3% of patients experienced at 
least one serious adverse event. In the phase III study,19 the 
baseline characteristics of older age, poor cytogenetics and per-
formance status, BM blast >50%, and higher WBC and lower 
platelet counts were associated with shorter OS. In a subgroup 
analysis, even patients with higher blast counts (BM blasts 
≥30%) could enjoy a survival benefit from decitabine treat-
ment.20 Ten-day schedules of decitabine therapy have also been 
studied, and Bhatnagar, et al.21 reported outcomes with an 
overall response rate of 42% and a median OS of 9.0 months.
In the present study, 35.3% of older adult patients with AML 
achieved CR or CRi status after decitabine treatment with a 
dosing regimen of 20 mg/m2 for 5 days in 28-day cycles. In a 
univariate analysis, BM blasts, LDH, serum ferritin level, and 
BM iron were associated with CR after decitabine treatment 
(p=0.027, 0.049, 0.036, and 0.033, respectively). The significance 
of lower BM blast percentage at diagnosis to predicting the 
decitabine response is similar to the results of a previous study.21 
Whereas BM blast and LDH are types of cancer cell factors af-
fecting the treatment response to decitabine, iron status, such 
as serum ferritin or BM iron, might be a microenvironmental 
factor. Ferritin is a well-known indicator of the body’s iron store 
and has various activities, such as that of an acute phase reac-
tant, antioxidant, or growth factor for AML cell lines.22,23 Hyper-
ferritinemia is a poor risk factor in patients with hematologic 
malignancies, probably because of the adverse impact of body 
iron accumulation in transfusion-dependent patients.24-27 How-
ever, hyperferritinemia might also affect prognosis through 
mechanisms other than iron accumulation, because several 
studies have demonstrated that even patients with hyperferri-
tinemia at diagnosis without prior transfusion have poor prog-
nosis.28,29 We could not perform a multivariate analysis because 
of the small study sample, so further study is necessary to eluci-
date the exact prognostic impact of baseline variables, such as 
serum ferritin, LDH, and BM blast percentage, and to identify 
patients that will likely benefit from decitabine treatment.
As decitabine must be incorporated into DNA to inhibit 
DNA methylation, it is necessary to give more applications of 
decitabine than that for conventional chemotherapy to con-
clude the activity of the drug against AML.5 In our study, contin-
uous decitabine treatment led to one of the six patients (16.7%) 
who had PR status after two cycles of decitabine achieving CR 
after the fourth cycle. In fact, six patients (35.3%) achieved either 
CR or CRi after a median 3.0 cycles (range, 2–4) of decitabine 
treatment. Similarly, one study reported that up to nine cycles of 
decitabine treatment were required to achieve CR in elderly pa-
tients with AML.10 Taken together, these data suggest that the ef-
fectiveness of decitabine therapy should not be determined too 
early, and at least four cycles of decitabine treatment should be 
given to patients to obtain the best response, unless there is 
strong evidence of a lack of response, such as an increase in leu-
kemic blast, despite decitabine therapy.
In summary, our study showed that decitabine treatment 
with a 5-day schedule is effective and well tolerated in Korean 
older adults with newly diagnosed AML. Therefore, decitabine 
could be recommended as a first-line treatment for such pa-
tients. A randomized prospective phase III trial comparing 
decitabine with standard 7+3 chemotherapy in patients with 
AML who are at least 60 years of age (NCT02172872) is current-
ly recruiting participants and will further address the role of 
decitabine.
Table 2. Hematologic and Non-Hematologic Toxicity of Decitabine 
Treatment
Toxicity No. of patients % (per 24 patients)
Febrile neutropenia
Grade 3/grade 4 5/2 20.8/8.3
Fatigue
Grade 2/grade 3 1/2 4.2/8.3
Cardiovascular toxicity
Heart failure (grade 3) 1 4.2
Pulmonary thromboembolism    
  (grade 4)
1 4.2
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